Collegium Pharmaceutical
COLL
eBay
EBAY
Halozyme Therapeutics
HALO
SilverCrest Metals
SILV
Workday
WDAY
(Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 51.51%8.09M | 46.28%7.91M | 25.00%24.95M | 35.28%7.26M | 36.32%6.94M | 8.20%5.34M | 18.45%5.41M | 9.94%19.96M | 8.66%5.37M | 7.17%5.09M |
Operating revenue | 51.51%8.09M | 46.28%7.91M | 25.00%24.95M | 35.28%7.26M | 36.32%6.94M | 8.20%5.34M | 18.45%5.41M | 9.94%19.96M | 8.66%5.37M | 7.17%5.09M |
Cost of revenue | 43.18%4.61M | 45.61%4.91M | 23.62%14.63M | 21.31%4.05M | 36.99%3.99M | 6.92%3.22M | 31.04%3.37M | 14.84%11.84M | 17.03%3.34M | 11.76%2.92M |
Gross profit | 64.20%3.48M | 47.41%3.01M | 27.00%10.32M | 58.24%3.21M | 35.43%2.95M | 10.20%2.12M | 2.21%2.04M | 3.49%8.12M | -2.77%2.03M | 1.59%2.18M |
Operating expense | 59.60%3.53M | 72.31%3.16M | 44.71%12.45M | 50.47%5.63M | 51.53%2.78M | 19.31%2.21M | 55.74%1.83M | -6.77%8.61M | 72.57%3.74M | -20.92%1.84M |
Selling and administrative expenses | 64.74%3.12M | 81.74%2.75M | 46.97%11.03M | 51.03%5.18M | 56.05%2.45M | 19.96%1.9M | 62.54%1.52M | -6.25%7.51M | 83.12%3.43M | -22.63%1.57M |
-General and administrative expense | 64.74%3.12M | 81.74%2.75M | 46.97%11.03M | 51.03%5.18M | 56.05%2.45M | 19.96%1.9M | 62.54%1.52M | -6.25%7.51M | 83.12%3.43M | -22.63%1.57M |
Depreciation amortization depletion | 28.77%407.51K | 27.52%406.65K | 29.22%1.42M | 44.23%448.89K | 25.14%336.1K | 15.55%316.47K | 29.93%318.88K | -10.18%1.1M | 5.57%311.23K | -9.18%268.58K |
-Depreciation and amortization | 28.77%407.51K | 27.52%406.65K | 29.22%1.42M | 44.23%448.89K | 25.14%336.1K | 15.55%316.47K | 29.93%318.88K | -10.18%1.1M | 5.57%311.23K | -9.18%268.58K |
Operating profit | 43.74%-53.06K | -176.32%-155.89K | -341.74%-2.14M | -41.25%-2.41M | -51.35%165.76K | -239.29%-94.31K | -75.00%204.26K | 64.99%-484.21K | -2,050.74%-1.71M | 290.26%340.7K |
Net non-operating interest income expense | -32.62%-203.09K | -51.37%-221.79K | -19.60%-654.95K | -57.61%-192.4K | -42.08%-162.9K | -0.03%-153.14K | 7.14%-146.52K | 26.73%-547.6K | 53.65%-122.07K | 37.24%-114.65K |
Non-operating interest expense | 32.22%85.76K | 24.89%69.6K | 9.24%232.58K | 72.26%58.73K | 95.05%53.26K | -17.10%64.86K | -23.93%55.73K | -53.56%212.9K | -81.11%34.09K | -70.40%27.31K |
Total other finance cost | 32.91%117.33K | 67.63%152.19K | 26.20%422.38K | 51.93%133.67K | 25.52%109.64K | 17.93%88.28K | 7.42%90.79K | 15.82%334.7K | 6.12%87.98K | -3.41%87.35K |
Other net income (expense) | -274.69%-653.2K | 361.96%249.8K | 84.65%-342.29K | 77.39%-214.03K | 92.05%-8.01K | 45.90%-174.33K | 106.28%54.07K | 40.46%-2.23M | 70.42%-946.57K | -104.57%-100.71K |
Gain on sale of security | -164.03%-18.47K | -67.45%-8.16K | -8,724.33%-650K | -20,307.54%-646.51K | 819.76%8.38K | -463.20%-7K | -171.88%-4.87K | -101.59%-7.37K | -92.58%-3.17K | -100.05%-1.16K |
Special income (charges) | -174.29%-684.38K | 75.39%-36.07K | 90.97%-231.21K | 122.02%228.13K | 67.86%-63.26K | 29.80%-249.51K | 84.92%-146.56K | 41.90%-2.56M | 68.65%-1.04M | 42.68%-196.81K |
-Less:Restructuring and merger&acquisition | 174.29%684.38K | -75.39%36.07K | -90.97%231.21K | -122.02%-228.13K | -67.86%63.26K | -29.80%249.51K | -84.92%146.56K | -41.90%2.56M | -68.65%1.04M | -42.68%196.81K |
Other non- operating income (expenses) | -39.58%49.65K | 43.07%294.03K | 59.67%538.92K | 120.75%204.36K | -51.80%46.88K | 138.45%82.17K | 81.51%205.51K | 71.25%337.52K | -13.11%92.57K | 201.71%97.27K |
Income before tax | -115.60%-909.35K | -214.37%-127.88K | 3.86%-3.14M | -1.54%-2.82M | -104.11%-5.15K | -3.48%-421.77K | 155.49%111.82K | 44.49%-3.26M | 21.58%-2.78M | -93.20%125.33K |
Income tax | 0 | 0 | -114.61%-86.79K | -155.94%-85.02K | -101.98%-7.84K | -234.07%-25.58K | 12.63%31.64K | 877.40%593.93K | 173.12%151.97K | 485.07%394.79K |
Net income | -260.74%-909.35K | -259.49%-127.88K | -9,537.93%-3.05M | -3.94%-2.88M | 100.98%2.69K | 40.92%-252.08K | -97.71%80.18K | 100.74%32.31K | 17.37%-2.77M | -117.04%-274.46K |
Net income continuous Operations | -129.52%-909.35K | -259.49%-127.88K | 20.92%-3.05M | 6.62%-2.74M | 101.00%2.69K | 7.14%-396.2K | 134.93%80.18K | 35.05%-3.86M | 12.13%-2.93M | -115.18%-269.46K |
Net income discontinuous operations | ---- | ---- | --0 | -190.62%-144.12K | --0 | --144.12K | ---- | 151.67%3.89M | 949.69%159.03K | 96.95%-5K |
Minority interest income | -7.78K | -20.61K | 43.58K | -64.18K | 0 | 0 | 0 | 0 | ||
Net income attributable to the parent company | -260.74%-909.35K | -249.79%-120.11K | -9,474.16%-3.03M | -5.51%-2.92M | 124.36%66.87K | 40.92%-252.08K | -97.71%80.18K | 100.74%32.31K | 17.37%-2.77M | -117.04%-274.46K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -260.74%-909.35K | -249.79%-120.11K | -9,474.16%-3.03M | -5.51%-2.92M | 124.36%66.87K | 40.92%-252.08K | -97.71%80.18K | 100.74%32.31K | 17.37%-2.77M | -117.04%-274.46K |
Basic earnings per share | -240.00%-0.034 | -266.67%-0.005 | -11,500.00%-0.114 | -9.52%-0.115 | 130.00%0.003 | 37.50%-0.01 | -97.73%0.003 | 100.50%0.001 | 30.92%-0.105 | -113.16%-0.01 |
Diluted earnings per share | -240.00%-0.034 | -266.67%-0.005 | -11,500.00%-0.114 | -9.52%-0.115 | 130.00%0.003 | 37.50%-0.01 | -97.73%0.003 | 100.50%0.001 | 30.92%-0.105 | -113.16%-0.01 |
Dividend per share | ||||||||||
Currency Unit | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |